Elite Pharmaceuticals (OTCQB: ELTP) schedules Q3 2026 results release and investor call
Rhea-AI Filing Summary
Elite Pharmaceuticals, Inc. filed a current report announcing it will release financial results for the third quarter of fiscal year 2026, ended December 31, 2025, on February 17, 2026. Management will host a conference call on February 18, 2026 at 11:30 EST to discuss the results and provide a corporate update.
Investors can join the call by dialing 1-800-346-7359 (domestic) or 1-973-528-0008 (international) using conference number 98840, and are invited to email general and financial questions in advance to dianne@elitepharma.com by the specified deadlines.
Positive
- None.
Negative
- None.
8-K Event Classification
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported)
ELITE PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
| (State or other jurisdiction | (Commission | (IRS Employer | ||
| of incorporation) | File Number) | Identification No.) |
(Address of principal executive offices)
(Registrant’s telephone number, including area code)
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||
| OTCQB |
Item 7.01. Regulation FD Disclosure.
On February 11, 2026, Elite Pharmaceuticals, Inc. (“Elite” or the “Company”) issued a press release announcing that the company will host a conference call to discuss its financial results for the third quarter of fiscal year 2026 ended December 31, 2025, on Wednesday, February 18th, 2026, at 11:30 AM EST. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated by reference herein.
Conference Call Information
| Date: | February 18, 2026 | |
| Time: | 11:30 AM EST | |
| Dial-in numbers: | 1-800-346-7359 (domestic) | |
| 1-973-528-0008 (international) | ||
| Conference number: | 98840 | |
| Questions: | dianne@elitepharma.com | |
| General questions by 5:00 PM EST on Monday, February 16, 2026 | ||
| Financial questions by 7:00 PM EST on Tuesday, February 17, 2026 |
The information disclosed in Item 2.02 above is incorporated into this Item 7.01. The information included in this Current Report on Form 8-K (including the exhibit hereto) is being furnished under Item 2.02, “Results of Operations and Financial Condition,” Item 7.01, “Regulation FD Disclosure” and Item 9.01 “Financial Statements and Exhibits” of Form 8-K. As such, the information (including the exhibit) herein shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be incorporated by reference into a filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing, except as shall be expressly set forth by specific reference in such a filing. This Current Report (including the exhibit hereto) will not be deemed an admission as to the materiality of any information required to be disclosed solely to satisfy the requirements of Regulation FD.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
| Exhibit No. | Description | |
| 99.1 | Press Release dated February 11, 2026 | |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document). |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Dated: February 11, 2026 | ELITE PHARMACEUTICALS, INC. |
| By: | /s/ Nasrat Hakim | |
| Nasrat Hakim, President and CEO |
Exhibit 99.1
Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update
and Discuss Third Quarter 2026 Financial Results on February 18, 2026
Financials for Third Quarter of Fiscal Year 2026 Ended December 31, 2025
will be released on Tuesday, February 17, 2026
Northvale, NJ – February 11, 2026: Elite Pharmaceuticals, Inc. (“Elite” or the “Company”) (OTCQB: ELTP), a specialty pharmaceutical company developing niche generic products, announced today that the third quarter financial results of the 2026 fiscal year will be released on Tuesday, February 17, 2026. Elite’s management will host a live conference call on Wednesday, February 18th, at 11:30 AM EST to discuss the company’s financial and operating results and provide a general business update. Stockholders should submit their questions to the company prior to the call.
| Date: | February 18, 2026 | |
| Time: | 11:30 AM EST | |
| Dial-in numbers: |
|
1-800-346-7359
(domestic) 1-973-528-0008 (international) |
| Conference number: | 98840 | |
| Questions: | dianne@elitepharma.com
General questions by 5:00 PM EST on Monday, February 16, 2026 Financial questions by 7:00 PM EST on Tuesday, February 17, 2026 | |
| Audio Replay: | https://elite.irpass.com/events_presentations |
About Elite Pharmaceuticals, Inc.
Elite Pharmaceuticals, Inc. is a specialty pharmaceutical company that develops, manufactures, and distributes niche generic products. Elite’s product lines consist of immediate-release and controlled-release, solid oral dose products, which are marketed under the Elite Laboratories label, as well as pursuant to licenses granted to third-party pharmaceutical marketing and distribution organizations. Elite operates a cGMP and DEA registered facility for research, development, and manufacturing located in Northvale, NJ. For more information, visit www.elitepharma.com.
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including, without limitation, those related to the effects, if any, on future results, performance or other expectations that may have some correlation to the subject matter of this press release. Readers are cautioned that such forward-looking statements involve, without limitation, risks, uncertainties, and other factors not under the control of Elite, which may cause actual results, performance or achievements of Elite to be materially different from the results, performance or other expectations that may be implied by these forward-looking statements. These forward-looking statements may include statements regarding the expected timing of approval, if at all, of products by the FDA and the actions the FDA may require of Elite in order to obtain such approvals. These forward-looking statements are not guarantees of future action or performance. These risks and other factors are discussed, without limitation, in Elite’s filings with the Securities and Exchange Commission, including its reports on forms 10-K, 10-Q, and 8-K. Elite is under no obligation to update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.
Contact:
For Elite Pharmaceuticals, Inc.
Dianne Will, Investor Relations, 518-398-6222
Dianne@elitepharma.com
www.elitepharma.com